Severe asthma

In patients with severe asthma, Alvesco^® also allows for an early and sustained reduction of oral steroid dose, whilst maintaining asthma control as well as lung function and minimizing systemic exposure.^1-3

Figure 1: A high dose of Alvesco^® (640µg/day) reduces asthma symptoms in moderate and severe asthma patients vs beclomethasone 800µg/day and Alvesco^® 320µg/day¹
Read more

Figure 2: Alvesco^® maintains lung function in moderate-to-severe persistent asthma previously well-controlled by high doses of ICS at baseline²
Read more 

Figure 3: At high doses, Alvesco^® allows an early and sustained reduction of oral steroid dose, whilst maintaining asthma control and minimizing systemic exposure³
Read more 

References:

1. Adachi M, Ishihara K, Inoue H, et al. Efficacy and safety of inhaled ciclesonide compared with chlorofluorocarbon beclomethasone dipropionate in adults with moderate to severe persistent asthma. Respirology 2007;12:573-80
2. Bateman E, Karpel J, Casale T, et al. Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma. Chest 2006;129:1176-87
3. Bateman ED, Linnhof AE, Homik L, et al. Comparison of twice-daily inhaled ciclesonide and fluticasone propionate in patients with moderate-to-severe persistent asthma. Pulm Pharmacol Ther 2008;21:264-275